SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study

Cited by (1,002)

Items 701–800 of 1,002

1. To Replicate or Not to Replicate: The Case of Pharmacogenetic Studies
   Stella W. Aslibekyan, Steven A. Claas, Donna K. Arnett · 2013 · Circulation Cardiovascular Genetics
2. ACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution
   David R. Holmes, Jeffrey A. Becker, Christopher Bull Granger, Marian C. Limacher, Robert Lee Page II, Cathy A. Sila, Joseph P. Drozda, Joseph G. Cacchione, Blair D. Erb, Robert A. Harrington et al. · 2011 · Journal of the American College of Cardiology
3. Advances in the Pharmacogenomics of Adverse Drug Reactions
   Susannah L. Collins, Daniel F. Carr, Munir Pirmohamed · 2015 · Drug Safety
4. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia
   Christina Diane Drenberg, SW Paugh, Stanley B Pounds, L Shi, SJ Orwick, Lei Li, Shuiying Hu, AA Gibson, RC Ribeiro, Jeffrey E. Rubnitz et al. · 2015 · Clinical Pharmacology & Therapeutics
5. Cardiovascular events, diabetes and guidelines: the virtue of simplicity
   Ricardo J. Esper, Roberto A. Nordaby · 2019 · Cardiovascular Diabetology
6. Methodological and statistical issues in pharmacogenomics
   Bas J.M. Peters, Andréi S. Rodin, Anthonius de Boer, Anke H. Maitland‐van der Zee · 2010 · Journal of Pharmacy and Pharmacology
7. Genomics and personalized medicine
   Wolfgang Sadée · 2011 · International Journal of Pharmaceutics
8. SLCO1B1Variants and Statin-Induced Myopathy
   Georgirene D. Vladutiu, Paul J. Isackson · 2009 · New England Journal of Medicine
9. Statins: A Potential Therapeutic Addition to Treatment for Aneurysmal Subarachnoid Hemorrhage?
   Mohammed Sabri, Robert Loch Macdonald · 2010 · World Neurosurgery
10. Drug–gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval
    Christy L. Avery, Colleen M. Sitlani, Dan E. Arking, Donna K. Arnett, Joshua C. Bis, Eric Boerwinkle, Brendan Martin Buckley, Yii‐Der Ida Chen, Anton J.M. de Craen, Mark Eijgelsheim et al. · 2013 · The Pharmacogenomics Journal
11. Integrative Genomics Strategies to Elucidate the Complexity of Drug Response
    Andrew Kasarskis, Xia Yang, Eric E. Schadt · 2011 · Pharmacogenomics
12. Introduction to Clinical Pharmacology
    Rommel G. Tirona, Richard B. Kim · 2016 · Elsevier eBooks
13. Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit
    Shuqin Zhou, Debra J. Skaar, Pamala A. Jacobson, R. Stephanie Huang · 2018 · Frontiers in Pharmacology
14. Central aortic pressure improves prediction of cardiovascular events compared to peripheral blood pressure in short-term follow-up of a hypertensive cohort
    Junli Zuo, Guili Chang, Isabella Tan, Mark Butlin, Shaoli Chu, Alberto P. Avolio · 2018 · Clinical and Experimental Hypertension
15. Interindividual Diversity in Expression of Organic Anion Uptake Transporters in Normal and Cirrhotic Human Liver
    Tatsuya Taniguchi, Alana Zanetti-Yabur, Pijun Wang, Mykhaylo Usyk, Robert David Burk, Allan W. Wolkoff · 2020 · Hepatology Communications
16. Safety of Statins and Nonstatins for Treatment of Dyslipidemia
    Connie B. Newman · 2022 · Endocrinology and Metabolism Clinics of North America
17. Statin associated muscle symptoms: An update and review
    Weston Dicken, Anurag Mehta, Angelos D. Karagiannis, Vardhmaan Jain, Michael Vavuranakis, Laurence S. Sperling, Dimitri C. Cassimatis · 2022 · Progress in Cardiovascular Diseases
18. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin
    Ilaria Iacobucci, Annalisa Lonetti, Anna Candoni, Marco Sazzini, Cristina Papayannidis, Serena Formica, Emanuela Ottaviani, Anna Ferrari, Angela Michelutti, E Simeone et al. · 2012 · The Pharmacogenomics Journal
19. Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug–drug interaction to support regulatory submissions
    Pradeep Kumar Sharma, Victoria Holmes, Robert Elsby, Craig Lambert, Dominic D. Surry · 2009 · Xenobiotica
20. GATM locus does not replicate in rhabdomyolysis study
    James S. Floyd, Joshua C. Bis, Jennifer A. Brody, Susan R. Heckbert, Kenneth M. Rice, Bruce M. Psaty · 2014 · Nature
21. Pharmacogenomics discovery and implementation in genome‐wide association studies era
    Xiuqin Ni, Wei Zhang, R. Stephanie Huang · 2012 · WIREs Systems Biology and Medicine
22. Predicting inhaled corticosteroid response in asthma with two associated SNPs
    Michael J. McGeachie, A C Wu, H-H Chang, J J Lima, Stephen P. Peters, Kelan G. Tantisira · 2012 · The Pharmacogenomics Journal
23. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects
    Nuthalapati Ramakumari, Bobbala Indumathi, Shiva Krishna Katkam, Vijay Kumar Kutala · 2018 · Indian Heart Journal
24. Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy
    Sidaway, J., Wang, Y., Marsden, A. M., Orton, T. C., Westwood, F. R., Azuma, C. T., Scott, R. C. · 2009 · Xenobiotica
25. Do MDR1 and SLCO1B1 Polymorphisms Influence the Therapeutic Response to Atorvastatin? A Study on a Cohort of Egyptian Patients with Hypercholesterolemia
    Mona Farag Shabana, Amal Mishriki, Marianne Samir Makboul Issac, Sameh Bakhoum · 2013 · Molecular Diagnosis & Therapy
26. Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus
    Kouji Kajinami, Kawai Yasusyuki · 2011 · Drug Design Development and Therapy
27. Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine
    Cristina Lucía Dávila-Fajardo, Xando Díaz-Villamarín, Alba Antúnez-Rodríguez, Ana Estefanía Fernández-Gómez, Paloma García-Navas, Luis Javier Martínez-González, José Augusto Dávila-Fajardo, José Cabeza Barrera · 2019 · Genes
28. Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics
    Yingmin Nie, Jingjie Yang, Shuai Liu, Ruiqi Sun, Huihui Chen, Nan Long, Rui Shuang Jiang, Chunshan Gui · 2019 · Xenobiotica
29. Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease
    Tariq E. Farrah, Atul Anand, Peter James Gallacher, Robert A. Kimmitt, Edwin Carter, James W. Dear, Nicholas L. Mills, David John Webb, Neeraj Dhaun · 2019 · Hypertension
30. Proprotein convertase subtilisin/kexin type 9 in kidney disease
    David Schmit, Danilo Fliser, Thimoteus Speer · 2019 · Nephrology Dialysis Transplantation
31. Interaction of Three Regiospecific Amino Acid Residues Is Required for OATP1B1 Gain of OATP1B3 Substrate Specificity
    Marianne K. DeGorter, Richard H. Ho, Brenda F. Leake, Rommel G. Tirona, Richard B. Kim · 2012 · Molecular Pharmaceutics
32. Systematic review on evidence of the effectiveness of cholesterol-lowering drugs
    Abhaya Gupta, Veronique Guyomard, Michele Zaman, Habib U. Rehman, Phyo Kyaw Myint · 2010 · Advances in Therapy
33. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population
    Eustathia Giannakopoulou, Georgia Ragia, Vana Kolovou, Anna Tavridou, Alexandros D. Tselepis, Moses Elisaf, Genovefa D. Kolovou, Vangelis G. Manolopoulos · 2014 · Molecular Biology Reports
34. Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort
    Henriette E. Meyer zu Schwabedissen, Martin Albers, Sebastian Edgar Baumeister, Christian Rimmbach, Matthias A. Nauck, Henri Wallaschofski, Werner Siegmund, Henry Völzke, Heyo K. Kroemer · 2014 · Pharmacogenetics and Genomics
35. Statin Dose in Asians: Is Pharmacogenetics Relevant?
    Ping Wang · 2011 · Pharmacogenomics
36. Case‐only genome‐wide interaction study of disease risk, prognosis and treatment
    Brandon L. Pierce, Habibul Ahsan · 2009 · Genetic Epidemiology
37. Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions
    Taleah Farasyn, Alexandra Crowe, Oliver J. D. Hatley, Sibylle Neuhoff, Khondoker Alam, Jean E. Kanyo, TuKiet T. Lam, Kai Ding, Wei Yue · 2019 · Journal of Pharmaceutical Sciences
38. Islet amyloidosis in a child with type 1 diabetes
    Maria L. Beery, Laura M. Jacobsen, Mark A. Atkinson, Alexandra E. Butler, Martha Campbell‐Thompson · 2019 · Islets
39. When the same treatment has different response: The role of pharmacogenomics in statin therapy
    Edward Zheng, Paulina Madura, Jakub Grandos, Marlena Broncel, Agnieszka Pawlos, Ewelina Woźniak, Paulina Gorzelak‐Pabiś · 2023 · Biomedicine & Pharmacotherapy
40. Fluorescent probes for the dual investigation of MRP2 and OATP1B1 function and drug interactions
    Virág Székely, Izabel Patik, Orsolya Ungvári, Ágnes Telbisz, Gergely Szakács, Éva Bakos, Csilla Özvegy‐Laczka · 2020 · European Journal of Pharmaceutical Sciences
41. Actionable pharmacogenetic variants in Hong Kong Chinese exome sequencing data and projected prescription impact in the Hong Kong population
    Mullin H.C. Yu, Marcus Chun Yin Chan, Claudia Ching Yan Chung, Andrew Wang Tat Li, Chara Yin Wa Yip, Christopher Chun Yu Mak, Jeffrey Fong Ting Chau, Mianne Lee, Jasmine Lee Fong Fung, Mandy Ho‐Yin Tsang et al. · 2021 · PLoS Genetics
42. Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy
    Alberto Muñoz, Florencia D. Pollarsky, Mónica Marino, Mariano Cartier, Horacio Vázquez, Pablo Salgado, Gustavo Romero · 2021 · World Journal of Gastroenterology
43. Application of principal component analysis to pharmacogenomic studies in Canada
    Henk Visscher, Colin J. Ross, Marie‐Pierre Dubé, Andrew M K Brown, M S Phillips, Bruce Carleton, Michael R. Hayden · 2009 · The Pharmacogenomics Journal
44. Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis
    Henriette E. Meyer zu Schwabedissen, Joseph A. Ware, David Finkelstein, Amarjit S. Chaudhry, Sara E. Mansell, Matilde Leon‐Ponte, Stephen C. Strom, Hani Zaher, Ute I. Schwarz, David J. Freeman et al. · 2011 · Hepatology
45. Effect of HMGCR Variant Alleles on Low‐Density Lipoprotein Cholesterol—Lowering Response to Atorvastatin in Healthy Korean Subjects
    Jae‐Yong Chung, Sung Kweon Cho, Eun Sil Oh, Dong Hwan Lee, Lay Ahyoung Lim, Seong Bok Jang, Yoon Jung Lee, Kyungsoo Park, Min Soo Park · 2011 · The Journal of Clinical Pharmacology
46. Genetics of lipid disorders
    James P. Pirruccello, Sekar Kathiresan · 2010 · Current Opinion in Cardiology
47. Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia
    Ahmed Abbas, J. J. Milles, Sudarshan Ramachandran · 2012 · Clinical Medicine Insights Endocrinology and Diabetes
48. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments
    Elliot M. Berinstein, Andrew P. Levy · 2017 · Expert Opinion on Drug Metabolism & Toxicology
49. Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews
    Yitian Zhou, Volker Martin Lauschke · 2018 · Journal of Medical Genetics
50. Impact of SLCO 1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review
    Jason L. Vassy, Sojeong Chun, Sanjay Advani, Sophie A. Ludin, Jason G Smith, Elaine C. Alligood · 2018 · Clinical Pharmacology & Therapeutics
51. High-dose atorvastatin therapy progressively decreases skeletal muscle mitochondrial respiratory capacity in humans
    TERENCE EDWARD RYAN, Maria J. Torres, Chien‐Te Lin, Angela H. Clark, Patricia M. Brophy, Cheryl A. S. Smith, Cody D. Smith, E. Matthew Morris, John P. Thyfault, Peter Darrell Neufer · 2024 · JCI Insight
52. Personalized vascular medicine: Individualizing drug therapy
    Emil M. deGoma, Giovanni Rivera, Scott M. Lilly, M Haris U Usman, Emile R. Mohler · 2011 · Vascular Medicine
53. SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine
    Eleni Aklillu, Abiy Habtewold, Eliford Ngaimisi, Getnet Yimer, Sabina Ferdinand Mugusi, Wondwossen Amogne, Tasmin Reuter, Andreas Daniel Meid, Michael M. Hoffmann, Johanna Weiß · 2016 · OMICS A Journal of Integrative Biology
54. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada
    Hamid Tavakoli, KATE JOHNSON, J Mark FitzGerald, Don D. Sin, Andrea S. Gershon, Tetyana Kendzerska, Mohsen Sadatsafavi · 2019 · International Journal of COPD
55. Effect of SLCO1B1 T521C on Statin‐Related Myotoxicity With Use of Lovastatin and Atorvastatin
    Brian D. Lu, Laura Sun, Manuel Seraydarian, Thomas J. Hoffmann, Marisa Wong Medina, NEIL J. RISCH, Carlos Iribarren, Ronald M. Krauss, Akinyemi Oni‐Orisan · 2021 · Clinical Pharmacology & Therapeutics
56. Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.
    Joseph P. Kitzmiller, Philip F. Binkley, Saurabh R Pandey, Adam Suhy, Damiano Baldassarre, Katherine Hartmann · 2013 · PubMed
57. A Review of Pharmacogenetics of Adverse Drug Reactions in Elderly People
    Maurizio Cardelli, Francesca Marchegiani, Andrea Corsonello, Fabrizia Lattanzio, Mauro Provinciali · 2012 · Drug Safety
58. Interethnic Comparisons of Important Pharmacology Genes Using SNP Databases: Potential Application to Drug Regulatory Assessments
    Jieming Chen, Yik Ying Teo, Dorothy Toh, Cynthia Sung · 2010 · Pharmacogenomics
59. Prevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian population of Kerala
    Changanamkandath Rajesh, Ancy Yesudas, Lakshmi Mahadevan, P. K. Sajesh, Shankar K. Revu, Prasanna Kumar, Devi Santhosh, Sam Santhosh, JM Sashikumar, Velliyur Kanniappan Gopalakrishnan et al. · 2014 · Indian journal of human genetics
60. Statin intolerance
    P Sikka, S Kapoor, VK Bindra, Monica Sharma, Pravesh Vishwakarma, Kuldeep Kumar Saxena · 2011 · Journal of Postgraduate Medicine
61. Pharmacogenomics and adverse drug reactions: the case of statins
    Mariano Anibal Giorgi, Christian Caroli, Hernán Cohen Arazi, Guillermo Di Girolamo · 2011 · Expert Opinion on Pharmacotherapy
62. Pharmacogenomics: Historical Perspective and Current Status
    Rosane Charlab, Lei Zhang · 2013 · Methods in molecular biology
63. A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients
    Kimie Sai, Kouji Kajinami, Hironobu Akao, Mizuho Iwadare, Ryoko Sato-Ishida, Yasuyuki Kawai, Kenji Takeda, Takashi Tanimoto, Takashi Yamano, Takashi Akasaka et al. · 2016 · Drug Metabolism and Pharmacokinetics
64. Rheostat positions: A new classification of protein positions relevant to pharmacogenomics
    Aron W. Fenton, Braelyn M. Page, Arianna Spellman-Kruse, Bruno Hagenbuch, Liskin Swint‐Kruse · 2020 · Medicinal Chemistry Research
65. Prediction of Severe Adverse Drug Reactions Using Pharmacogenetic Biomarkers
    Masahiro Tohkin, Akihiro Ishiguro, Nahoko Kaniwa, Yoshiro Saito, Kouichi Kurose, Ryuichi Hasegawa · 2010 · Drug Metabolism and Pharmacokinetics
66. Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia
    Chang‐Min Chung, Ming‐Shyan Lin, Jen‐Te Hsu, Ju‐Feng Hsiao, Shih‐Tai Chang, Kuo‐Li Pan, Chun‐Liang Lin, Yu‐Sheng Lin · 2017 · Journal of clinical lipidology
67. Associations with metabolites in Chinese suggest new metabolic roles in Alzheimer’s and Parkinson’s diseases
    Jin Fang Chai, Suryaprakash Raichur, Ing Wei Khor, Federico Tesio Torta, Wee Siong Chew, Deron Raymond Herr, Jianhong Ching, Jean Paul Kovalik, Chin Meng Khoo, Markus Rene Wenk et al. · 2019 · Human Molecular Genetics
68. Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts
    Carolina Dagli-Hernandez, Yitian Zhou, Volker Martin Lauschke, Fabiana Dalla Vecchia Genvigir, Thiago Dominguez Crespo Hirata, Mário Hiroyuki Hirata, Rosário Dominguez Crespo Hirata · 2021 · Pharmacological Reports
69. Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates
    Samantha J. Medwid, Hayley R. Price, Daniel P. Taylor, Jaymie Mailloux, Ute I. Schwarz, Richard B. Kim, Rommel G. Tirona · 2021 · Frontiers in Pharmacology
70. Adverse drug reactions
    Robin Esmond Ferner, Patricia McGettigan · 2018 · BMJ
71. Management of patients with statin intolerance
    Alexandra Nicole Martirossian, Anne Carol Goldberg · 2022 · Best Practice & Research Clinical Endocrinology & Metabolism
72. Identification and Mechanistic Investigation of Drug–Drug Interactions Associated With Myopathy: A Translational Approach
    Xu Han, Sara K. Quinney, Zaiqi Wang, Pengyue Zhang, Jon D Duke, Zeruesenay Desta, Jeffrey S. Elmendorf, David Alastair Flockhart, Lang Li · 2015 · Clinical Pharmacology & Therapeutics
73. Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression
    Kouichi Kurose, Kazuyuki Hiratsuka, Kazuya Ishiwata, Jun Nishikawa, Shinpei Nonen, Junichi Azuma, Masaki Kato, Masataka Wakeno, Gaku Okugawa, Toshihiko Kinoshita et al. · 2012 · Psychiatry Research
74. Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution
    Jeffrey A. Pfefferkorn, John Litchfield, R. H. Hutchings, Xue-Min Cheng, Scott D. Larsen, Bruce J. Auerbach, Mark R. Bush, Chitase Lee, Noe O. Erasga, Daniel M. Bowles et al. · 2010 · Bioorganic & Medicinal Chemistry Letters
75. The Acute (Cerebro)Vascular Effects of Statins
    Vincent Prinz, Matthias Endres · 2009 · Anesthesia & Analgesia
76. Influence ofSLCO1B1Polymorphisms on the Drug‐Drug Interaction Between Darunavir/Ritonavir and Pravastatin
    Christina L. Aquilante, Jennifer J. Kiser, Peter L. Anderson, Uwe Christians, Lisa A. Kosmiski, Elizabeth B. Daily, Keith L. Hoffman, Charles Wilfley Hopley, Julie A. Predhomme, Björn Schniedewind et al. · 2011 · The Journal of Clinical Pharmacology
77. The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups
    Alberico Luigi Catapano, Peter Paul Toth, Joanne E. Tomassini, Andrew M. Tershakovec · 2013 · Clinical Lipidology
78. The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: Evidence from clinical trials
    Alawi A.A. Alsheikh-Ali, Richard H. Karas · 2009 · Current Atherosclerosis Reports
79. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals
    Yalena Prado, Nicolás Saavedra, Tomás Zambrano, Jenny Lagos, Alexy Rosales, Luis Antonio Salazar · 2015 · International Journal of Molecular Sciences
80. Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis
    Beatrice Nefussy, Jonathan Hirsch, Merit Cudkowicz, Vivian E. Drory · 2010 · Journal of the Neurological Sciences
81. More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter‐Mediated Clearances
    Arian Emami Riedmaier, Howard J. Burt, Khaled Abduljalil, Sibylle Neuhoff · 2016 · The Journal of Clinical Pharmacology
82. ACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution
    David R. Holmes, Jeffrey A. Becker, Christopher Bull Granger, Marian C. Limacher, Robert Lee Page II, Cathy A. Sila · 2011 · Circulation
83. Translating genomics into improved healthcare
    Aroon Dinesh Hingorani, Tina Shah, Meena Kumari B, Reecha Sofat, Liam L Smeeth · 2010 · BMJ
84. Severe Rhabdomyolysis Associated with Simvastatin and Role of Ciprofloxacin and Amlodipine Coadministration
    Nicolas De Schryver, Xavier Wittebole, Peter Van den Bergh, Vincent Haufroid, Eric Jean Goffin, Philippe E. Hantson · 2015 · Case Reports in Nephrology
85. Comentarios a las guías de práctica clínica sobre manejo de las dislipemias de la Sociedad Europea de Cardiología y la Sociedad Europea de Aterosclerosis 2011. Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología
    Manuel P. Anguita, Eduardo Alegría, Vivencio Barrios, José Antonio Casasnovas, Carlos Escobar, Monserrat León, Emilio Luengo, José L. Llisterri, Ángel Alonso, Angel R. Cequier et al. · 2011 · Revista Española de Cardiología
86. Muscle weakness: Understanding the principles of myopathy and neuropathy in the critically ill patient and the management options
    Miguel Ángel Martínez‐García, Juan Carlos Montejo González, Abelardo García-de-Lorenzo y Mateos, Susana Teijeira · 2019 · Clinical Nutrition
87. Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy
    Olga Mucha, Paulina Podkalicka, Katarzyna Kaziród, Emilia Samborowska, Józef Dulak, Agnieszka Łoboda · 2021 · Skeletal Muscle
88. SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care
    Deepak Voora, Jordan Baye, Adam McDermaid, Smitha Narayana Gowda, Russell A. Wilke, Anna Nicole Myrmoe, Catherine Hajek, Eric A. Larson · 2022 · Clinical Pharmacology & Therapeutics
89. Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.
    A. Nies, E. Schaeffeler, M. Schwab · 2022 · Pharmacology and Therapeutics
90. Implementation of pharmacogenomics: Where are we now?
    Samantha J. Medwid, Richard B. Kim · 2022 · British Journal of Clinical Pharmacology
91. Development of a Population Pharmacokinetic Model for Atorvastatin Acid and Its Lactone Metabolite
    Rajesh Narwal, Fatemeh Akhlaghi, Anders Åsberg, Monica Hermann, Sara E Rosenbaum · 2010 · Clinical Pharmacokinetics
92. Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C Polymorphisms and Overall Survival of Breast Cancer Patients after Tamoxifen Therapy
    Haitang Xie · 2015 · Medical Science Monitor
93. Pharmacogenomics of Lipid-Lowering Therapies
    Miao Hu, Brian Tomlinson · 2013 · Pharmacogenomics
94. Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin
    Matti K. Itkonen, Aleksi Tornio, Mikko Neuvonen, Pertti J. Neuvonen, Mikko Niemi, Janne T. Backman · 2015 · Drug Metabolism and Disposition
95. Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population
    Karin Badavievich Mirzaev, Denis S. Fedorinov, Dmitriy V. Ivashchenko, Dmitry Alekseevich Sychev · 2019 · Rational Pharmacotherapy in Cardiology
96. Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy
    Najmeh Ahangari, Mohammad Doosti, Majid Ghayour‐Mobarhan, Amirhossein Sahebkar, Gordon A. Ferns, Alireza Pasdar · 2020 · Annals of Medicine
97. Quantitative Population Pharmacokinetic Analysis of Pravastatin Using an Enterohepatic Circulation Model Combined With Pharmacogenomic Information onSLCO1B1andABCC2Polymorphisms
    Takafumi Ide, Tomohiro Sasaki, Kazuya Maeda, Shun Higuchi, Yuichi Sugiyama, Ichiro Ieiri · 2009 · The Journal of Clinical Pharmacology
98. Detection of Statin Cytotoxicity Is Increased in Cells Expressing the OATP1B1 Transporter
    Xun Zhang, Renato J. Scialis, Bo Feng, Karen L. Leach · 2013 · Toxicological Sciences
99. Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug–Drug Interactions
    Nicola Ferri, Elisa Colombo, Alberto Corsini · 2024 · Pharmaceutics
100. Pharmacogenomics, Lipid Disorders, and Treatment Options
     Steven E. Gryn, Robert Alexander Hegele · 2014 · Clinical Pharmacology & Therapeutics